Famotidine NDC 27241-249

NDC codes

FDA NDC Directory

Product NDC (as listed)27241-249Labeler and product segments. Claims need a package NDC.

Product NDC at billing width27241-0249Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
27241-249-49	27241024949	50 mL in 1 BOTTLE (27241-249-49)Marketed from Apr 25, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Famotidine
Generic name (nonproprietary): famotidine
Active ingredients: Famotidine — 40 mg/5mL
Dosage form: For suspension
Route: Oral
Labeler: Ajanta Pharma USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217529
Marketing start: Apr 25, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Histamine H2 Receptor Antagonists (Mechanism)
Identifiers: Product ID 27241-249_041ec6f5-5445-4403-9e76-12c2cda8eea7SPL ID 041ec6f5-5445-4403-9e76-12c2cda8eea7SPL set ID a88e7069-230c-4105-ade0-a98968e18671RxCUI 310274UNII 5QZO15J2Z8UPC 0327241249495
Pharmacologic class: Histamine-2 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N427241024949 followed by a unit qualifier and the quantity

Package 27241-0249-49. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 30, 2025.

Indications (excerpt from the label)

Famotidine for oral suspension is indicated in adults for the treatment of: active duodenal ulcer (DU). active gastric ulcer (GU). symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of duodenal ulcer recurrence. Famotidine for oral suspension is indicated in pediatric patients 1 year of age and older for the treatment of: peptic ulcer disease. GERD with or without esophagitis and ulcerations. Famotidine for oral suspension is indicated in pediatric patients from birth to less than 1 year …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)